Search research articles
Contact Us
Filters
Showing results (381-390 of 740) with videos related to
Page
of 74
Sort By:
British Journal of Haematology
|
July 13, 2010
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients
Efstathios Kastritis, Maria Roussou, Michalis Michael, et al.
Cancers
|
October 8, 2020
Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
Tina Bagratuni, Dimitrios Patseas, Nefeli Mavrianou-Koutsoukou, et al.
Anticancer Research
|
October 3, 2014
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group
Vasilios Karavasilis, Paris Kosmidis, Konstantinos N Syrigos, et al.
Leukemia & Lymphoma
|
August 8, 2017
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases
Dimitrios C Ziogas, Evangelos Terpos, Maria Gavriatopoulou, et al.
British Journal of Haematology
|
June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic
Efstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
Blood
|
January 12, 2011
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia
Sandra Grass, Klaus-Dieter Preuss, Alexandra Wikowicz, et al.
Blood
|
September 19, 2008
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang, Meletios A Dimopoulos, Christine Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2013
Reply to S. Girnius et al
Giovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
American Journal of Hematology
|
August 29, 2013
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group
Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, et al.
Haematologica
|
October 30, 2016
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
Efstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
Page
of 74
Search research articles
Search
Showing results (381-390 of 740) with videos related to
Sort By:
Page
of 74
British Journal of Haematology
|
July 13, 2010
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients
Efstathios Kastritis, Maria Roussou, Michalis Michael, et al.
Cancers
|
October 8, 2020
Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
Tina Bagratuni, Dimitrios Patseas, Nefeli Mavrianou-Koutsoukou, et al.
Anticancer Research
|
October 3, 2014
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group
Vasilios Karavasilis, Paris Kosmidis, Konstantinos N Syrigos, et al.
Leukemia & Lymphoma
|
August 8, 2017
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases
Dimitrios C Ziogas, Evangelos Terpos, Maria Gavriatopoulou, et al.
British Journal of Haematology
|
June 2, 2020
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic
Efstathios Kastritis, Ashutosh Wechalekar, Stefan Schönland, et al.
Blood
|
January 12, 2011
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia
Sandra Grass, Klaus-Dieter Preuss, Alexandra Wikowicz, et al.
Blood
|
September 19, 2008
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang, Meletios A Dimopoulos, Christine Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2013
Reply to S. Girnius et al
Giovanni Palladini, Angela Dispenzieri, Morie Gertz, et al.
American Journal of Hematology
|
August 29, 2013
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group
Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, et al.
Haematologica
|
October 30, 2016
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
Efstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
Page
of 74